Anlon Healthcare Limited — PPTs, 05-08-2026: Investor Presentation

Here's a summary of Anlon Healthcare's investor presentation, focusing on key highlights for retail investors:

**1. Business Performance:**

Anlon Healthcare has shown strong growth, with consolidated revenues climbing from ₹66.58 Cr in FY24 to ₹172.22 Cr in FY26. This growth was significantly boosted by recent acquisitions and an expanding product portfolio. The company's revenue mix is shifting, with Pharmaceutical Intermediates now contributing over 71% of revenue in FY26, up from 35.70% in FY25, while APIs contribution has decreased to 26.37%.

**2. Growth Drivers or Strategy:**

Anlon is strategically transforming into an integrated pharmaceutical company by entering the Finished Dosage Formulations (FDFs) segment through acquisitions like Remember India Health Links. They are also diversifying into Industrial & Fine Chemicals to reduce dependence on the pharma cycle. A key focus is backward integration for critical raw materials and expanding manufacturing capacity to a projected 1,400–1,600 MTPA.

**3. Recent Developments:**

The company has successfully completed acquisitions of Bizotic Lifescience Pvt. Ltd. and Apiqo Organics Pvt. Ltd., which are now subsidiaries. Additionally, Remember India Health Links Pvt. Ltd. has also become a subsidiary. These moves are expected to accelerate capacity expansion and strengthen regulatory readiness.

**4. Key Financial Metrics:**

EBITDA has grown robustly from ₹15.57 Cr in FY24 to ₹47.77 Cr in FY26, with margins improving to 27.74%. Profit After Tax (PAT) has also seen a significant increase from ₹9.66 Cr in FY24 to ₹29.09 Cr in FY26. The company is projecting a 30% revenue CAGR over the next three years.

**5. Management Commentary / Outlook:**

Management is optimistic about future growth, driven by the integration of acquired businesses, new API launches in FY26-27, and expansion into new chemical segments. The company anticipates sustained EBITDA margins of 25-30% and aims for 3-5 DMF filings in FY26-27 to enhance regulated market penetration.